Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells-Reference-Cited by-同舟云学术

Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells

Published:2023-08-18 Issue:1 Volume:28 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Yang Yulin¹²,Zhong Fangmin¹,Jiang Junyao¹,Li Meiyong¹,Yao Fangyi¹,Liu Jing¹,Cheng Ying¹²,Xu Shuai¹²,Chen Song¹²,Zhang Haibin¹,Xu Yanmei¹,Huang Bo¹

Affiliation:

1. Jiangxi Province Key Laboratory of Laboratory Medicine, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, People’s Republic of China

2. School of Public Health, Nanchang University, Nanchang, People’s Republic of China

Funder

Natural Science Foundation of China

Natural Science Foundation of Jiangxi Province

Jiangxi Provincial Health Committee scientific research projects

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2023.2244856

Reference35 articles.

1. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

2. Chronic myeloid leukemia: mechanisms of blastic transformation

3. Molecular Pathways: BCR-ABL

4. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

5. Tyrosine phosphorylation of p62dok by p210bcr-abl inhibits RasGAP activity

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Combination treatments of imatinib with astaxanthin and crocin efficiently ameliorate antioxidant status, inflammation and cell death progression in imatinib-resistant chronic myeloid leukemia cells”;Molecular Biology Reports;2024-01-16